Gunderson Dettmer represented client Remix Therapeutics, a clinical stage biotechnology company, in the collaboration and license agreement with Roche for the discovery and development of small molecule therapeutics that modulate RNA processing.

Under the terms of the agreement, Remix will receive an upfront payment of $30 million and are eligible to receive up to $12 million in near-term milestone payments, as well as preclinical, clinical, commercial and sales milestones of up to $1 billion and tiered royalties. In exchange, Roche will have exclusive rights to specific targets. Remix will conduct discovery and preclinical activities with Roche, and Roche will be responsible for development and commercialization of any resulting products.

In the announcement of the collaboration, Remix Therapeutics President and Chief Executive Officer Peter Smith said, "We're excited to partner with a team with strong expertise and dedication to the field of interfering with targets at the RNA level. Our collaboration with Roche provides an opportunity to further leverage our REMaster drug discovery platform and translate our cutting-edge science into new medicines."

The Gunderson Dettmer deal team was led by Tim Ehrlich and Aliya Sanders.

Companies
Remix Therapeutics 
Roche